Evidence map›Paper›PMID 42113411›Full record

ReviewMolecular diversity2026

Imidazole Scaffolds against Staphylococcus aureus and MRSA: a medicinal chemistry review.

Supriyo Saha, Muskan Singh, Nikita Thapliyal, Shakir Ahamad, Shahnawaz Ali Bhat, Vikash Jakhmola

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Supriyo SahaDepartment of Pharmaceutical Chemistry, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India. supriyo9@gmail.com.ORCID http://orcid.org/0000-0003-1365-4698
Muskan SinghDepartment of Pharmaceutical Chemistry, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
Nikita ThapliyalDepartment of Pharmaceutical Chemistry, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
Shakir AhamadDepartment of Chemistry, C. M. Science College, Lalit Narayan Mithila University, Darbhanga, 846004, India.
Shahnawaz Ali BhatDepartment of Zoology, Aligarh Muslim University, Aligarh, India.
Vikash JakhmolaDepartment of Pharmaceutical Chemistry, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus infections remain a major clinical challenge due to rapid acquisition of antimicrobial resistance, exemplified by Methicillin-Resistant Staphylococcus aureus. The imidazole scaffold has attracted sustained interest owing to its chemical versatility and broad pharmacological relevance. This review provides the first comprehensive and critical summary of recent advances in the synthesis and anti-staphylococcal activity of structurally diverse imidazole derivatives, including benzimidazoles, metal complexes, mercapto- and polycyclic analogues, and hybrid conjugates with bioactive motifs such as indole, berberine, and rifamycin. Both conventional and enabling methodologies (microwave- and ultrasound-assisted synthesis) are evaluated, with key transformations encompassing condensations, transition-metal-catalyzed couplings, complexation, El-Saghier, and Groebke-Blackburn-Bienaymé reactions. Structure-activity relationship analyses reveal that indole-, rifamycin-, berberine-, and N-aryl-substituted imidazoles exhibit superior potency against resistant strains, whereas hydroxynaphthalene, 2-phenyl-benzimidazole, imidazothiadiazole, and isatin analogues often show diminished activity. Collectively, these insights provide a rational framework for designing next-generation imidazole-based anti-staphylococcal agents, while underscoring the need for comprehensive profiling of stability, toxicity, and PK/PD properties to enable clinical translation.

Indexed as

Anti-microbial resistanceImidazole-derivativesMRSAStaphylococcus aureusStructure–activity relationship

Identifiers

PMID42113411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.